ArticleOrphanet journal of rare diseases2021
Prevalence of extramammary Paget's disease in urban China: a population-based study.
Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence.Frontiers in immunology · 2024Pooled it
- Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).BMC cancer · 2026Trial
- Efficacy of Radiation Therapy in 106 Patients with Extramammary Paget Disease: A Retrospective Study.Advances in radiation oncology · 2026Article
- Management of Extramammary Paget Disease of the Male Genital Region: A Narrative Review and Two Case Reports.Journal of clinical medicine · 2026Review
- Comparison of clinical and dermoscopic features between extramammary Paget's disease and chronic eczema.Frontiers in medicine · 2026Article
- Case Report: Complete remission after radiotherapy in two cases of locally advanced extramammary Paget's disease of the perineum.Frontiers in oncology · 2026Article
- Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease.The oncologist · 2025Article
- Insights Into Mammary and Extramammary Paget's Disease: Diagnosis, Management, and Recent Advances.Cureus · 2025Review
- Assessing mortality risk and causes in extramammary Paget's disease: insights from a population-based study.Translational cancer research · 2025Article
- A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan.Scientific reports · 2025Article
- Primary scrotal Paget's disease: a case report and literature review.Frontiers in medicine · 2025Article
- PIK3CA inhibitor treatment for metastatic scrotal extramammary Paget's disease: a case report and literature review.AME case reports · 2025Article
- FOXM1: a new therapeutic target of extramammary Paget disease.Scientific reports · 2024Article
- Crafting Contours: A Comprehensive Guide to Scrotal Reconstruction.Life (Basel, Switzerland) · 2024Review
- Independent Risk Factors for Postoperative Recurrence of Patients with Primary Extramammary Paget's Disease: A Retrospective Analysis.Clinical, cosmetic and investigational dermatology · 2024Article
- Article
- Extramammary Paget's disease: Updates in the workup and management.Asian journal of urology · 2022Review
- Nomograms for predicting the prognosis of patients with penoscrotal extramammary Paget's disease: A retrospective study in the SEER database and two medical centers.Frontiers in oncology · 2022Article
- Extramammary Paget's Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments.Current oncology (Toronto, Ont.) · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtramammary Paget's disease (EMPD) is an intraepithelial adenocarcinoma. The chronic relapsing clinical course and unbearable clinical symptoms of extramammary Paget's disease usually result in a markedly diminished quality of life. No national data are available on descriptive epidemiology of EMPD in China, the most populous country over the world. This population-based study aimed to estimate the prevalence and associated sex and age patterns of EMPD in China.
methodsThis study was conducted using data from China's Urban Employee Basic Medical Insurance and Urban Resident Basic Medical Insurance, covering approximately 0.43 billion Chinese urban residents in 2016. Patients with EMPD were identified based on the diagnostic names and codes in claim data.
resultsA total of 53 males and 31 females with EMPD were found. The crude prevalence in 2016 was 0.04 per 100,000 population [95% confidence interval (CI) 0.02-0.06], ranging from 0.01 (95% CI 0.00-0.02) in North or Northeast China to 0.08 (95% CI 0.03-0.16) in Southwest China. The rate was higher in males (0.05, 95% CI 0.03-0.08) compared with females (0.03, 95% CI 0.02-0.05). The mean age of patients was 65.87 (standard deviation: 14.21) years, with the peak prevalence appeared in patients aged 70-79 (0.28, 95% CI 0.16-0.42).
conclusionsThe prevalence of EMPD was markedly lower than those in the United States and Europe, and varied across regions in China. Chinese patients were much younger, with significant male predominance. Further studies are warranted to examine potential pathophysiologic mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.